Bemiparin sodium - Rovi
Alternative Names: Anti-Factor Xa - Rovi; Badyket; Cibor; Hepadren; Heporax; Hibor; Ivor; Ivorat; Ivormax; LMWH-Rovi; Nautiol; RO-11; ZiborLatest Information Update: 26 Sep 2022
At a glance
- Originator Rovi
- Developer Berlin Chemie; Elder Pharmaceuticals; Menarini; Rovi; sigma-tau SpA; UCB; University of Navarra
- Class Antithrombotics; Glycosaminoglycans; Low molecular weight heparins
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Small cell lung cancer
Highest Development Phases
- Marketed Thromboembolism
- Phase II Small cell lung cancer
- Discontinued COVID 2019 infections; Diabetic foot ulcer
Most Recent Events
- 26 Sep 2022 Discontinued - Phase-II for COVID-2019 infections in Spain (SC)
- 07 Jun 2022 Syntax for Science and Fundación de investigación terminates a phase II trial in COVID-2019 infections in Spain (SC) due to lack of funding (NCT04420299)
- 04 Jun 2020 Phase-II clinical trials in COVID-2019 infections in Spain (SC) (NCT04420299)